CG ONCOLOGY, INC.

Communiqués CG Oncology, Inc.

Actions

CGON

US1569441009

Temps réel estimé Cboe BZX Autres places de cotation 18:31:44 06/06/2024			Varia. 5j.	Varia. 1 janv.
35,09 ^USD	-2,53%		+2,00%	0,00%

24/05	Mise à jour sectorielle : Les actions du secteur de la santé sont plus douces dans les échanges de l'après-midi de vendredi	MT
24/05	Les actions de CG Oncology bondissent après que la thérapie combinée potentielle pour le cancer de la vessie ait atteint le critère d'évaluation primaire de la phase 2	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC	18:15	AQ
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting	24/05	AQ
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates	09/05	AQ
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	06/05	AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	03/05	AQ
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024	26/04	AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024	24/04	AQ
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting	28/03	AQ
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer	27/02	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares	31/01	AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	30/01	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.

PROFITEZ-EN MAINTENANT